Auxilium Signs Sobi As Pfizer Replacement In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The maker of Xiaflex/Xiapex has found a new commercialization partner in the EU after its first partnership fell apart due to disappointing sales of the drug in those territories.
You may also be interested in...
Pending EU Approval Of Eloctate, Sobi Opts In To Second Hemophilia Program With Biogen
Sobi also gets two oral formulations of Orfadin for the rare genetic disorder HT-1 and is starting over with a new candidate in a collaboration with Affibody.
Auxilium Revamps Commercial Strategy For Xiaflex
The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.